Emerging Company Showcase

Transformative Innovations, Visionary Founders

Each company featured in the 2025 Emerging Company Showcase was nominated, reviewed and invited to present based upon their transformative innovations and the enterprising team. They presented before an panel of early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors.

2025 Presenting Companies

	Ancilia Biosciences Inc., New York, NY: Leveraging  CRISPR’s natural function in bacteria + computation to unlock the efficacy of first-in-class therapies for broad applications.
	Aspen Neuroscience, San Diego, CA: Developing autologous iPSC-derived dopaminergic neuron cell therapies to restore motor function in Parkinson’s disease
	Bioio, Inc., St. Louis, MO: Developing AI-driven small-molecule therapeutics that reverse cellular aging by restoring mitochondrial function and metabolic health.
	Calder Biosciences Inc., Brooklyn NY: Developing novel conformationally stabilized prefusion subunit vaccines for respiratory syncytial virus (RSV) and Influenza.
	Centron Bio, Cambridge, MA: Developing genetic medicines that cross the blood-brain barrier to provide better treatments for patients with neurodegenerative diseases.
	CrossBridge Bio, Houston, TX: Developing dual-payload antibody-drug conjugates (ADCs) with proprietary stable, enzymatically-cleavable linkers to enhance the treatment of solid tumors.
	D2B3 Bio, New Haven, CT: Developing a monoclonal antibody that transiently opens the blood-brain barrier to enable safe systemic delivery of therapeutics to the brain.
	EyeVision Pharma, New York, NY: Developing AI-designed ocular-restricted drug combinations in topical eye drops to inhibit axial elongation and prevent myopia progression.
	Foli Bio, New York, NY: Developing a stool-based transcriptomics platform to non-invasively profile the gut mucosa for precision medicine and drug development.
	Frezent, New York, NY: Developing a novel class of bifunctional therapeutic modalities, bispecific antibodies and antibody-drug conjugates, to target non-dividing, dormant cancer cells.
	GeneVentiv Therapeutics, Inc, Raleigh, NC: Developing gene therapies for hemophilia and Pompe disease with approaches designed for durable, long-term treatment.
	Nephrogen, New York, NY: Developing AI-engineered gene delivery vectors to enable curative AAV-based therapies for kidney and pancreatic diseases.
	Onselex Pharmaceuticals, New York, NY: Developing biodegradable nanoparticle-loaded oncology formulations to enable targeted drug delivery with reduced off-tumor toxicity.
	Piston Bio LLC, Morristown, NJ: Developing therapies to restore appetite and motivation in cancer cachexia and reactivate tumor antigen presentation to overcome immune checkpoint resistance.
	ProViZigen LLC, New York, NY: Developing a thermoresponsive hydrogel for targeted drug delivery to prevent post-traumatic osteoarthritis.
	Raadysan Biotech, Inc., Fishkill, NY: Developing first-in-class small molecule inhibitors of a novel DNA replication protein to selectively eliminate triple-negative breast cancer cells and improve patient survival.
	Seed Therapeutics, King of Prussia, PA: Pioneering molecular glue degraders to eliminate previously undruggable disease-causing proteins across multiple disease areas.
	Sidereal Therapeutics, New York, NY: Developing precision biologics that sequester catalytic iron to prevent acute kidney injury in high-risk settings.
	Sophrosyne Biosciences, New York, NY: Developing developmentally realistic neocortical tissue grafts to restore brain function following focal stroke.
	Telos Biotech, Inc., New York, NY: Developing a telomere-lengthening reagent to rejuvenate patient cells during cell therapy manufacturing, boosting their expansion, persistence, and anti-cancer potency.
	UbiquiTx. Inc., New York, NY: Using AI-driven proteome editing to design programmable chimeric ligands, enabling precise degradation and modulation of disease-causing proteins.
	Valenyx Therapeutics: New York, NY: Developing single-domain antibody-based ADCs and molecular glue conjugates for highly selective, potent treatment of solid tumors.
	Vivacelle Bio, Inc., Kansas City, MO: Developing phospholipid nanoparticle-based fluids (like VBI-S) to restore blood pressure and reverse organ failure in patients with septic shock and severe blood loss.
	XM Therapeutics, Inc., Providence, RI: Developing human extracellular matrix particles to restore tissue structure and function in heart failure and other chronic diseases.
	View the 2024 showcase presenters here.